Blog
RSS FeedPosted by Michael Wonder on 24 Oct 2025
Up to 6,000 patients to benefit from NICE-approved life-extending prostate cancer drug
24 October 2025 - People living with metastatic prostate cancer in England will gain access to a new treatment combination from ...
Posted by Michael Wonder on 23 Oct 2025
New life saving medicine free for rare disease
22 October 2025 - Australians with the extremely rare and life-threatening inherited disease, acid sphingomyelinase deficiency (ASMD) will now have ...
Posted by Michael Wonder on 22 Oct 2025
Updated information about Pharmac’s priority lists (September 2025)
21 October 2025 - Pharmac’s Pūahoaho Report provides the latest information about applications for medicines, vaccines, and related products that we’ve ...
Posted by Michael Wonder on 22 Oct 2025
Sarilumab for the treatment of children/adolescents 2-17 years of age with polyarticular or oligoarticular juvenile idiopathic arthritis
22 October 2025 - NICE is unable to make a recommendation on the use of sarilumab (Kevzara) for the treatment of ...
Posted by Michael Wonder on 22 Oct 2025
Clascoterone for the treatment of patients 12 years of age and older with acne vulgaris
22 October 2025 - NICE is unable to make a recommendation on the use of clascoterone (Winlevi) for the treatment of patients ...
Posted by Michael Wonder on 20 Oct 2025
PHARMAC proposes greater transparency for medicine funding decisions
20 October 2025 - PHARMAC is proposing changes to bring greater transparency and clarity to how medicine funding applications are ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 17 Oct 2025
Rare cancer lifeline comes with dual drug discounts
17 October 2025 - Two common immunotherapy drugs will now be subsidised for all advanced or metastatic cancers, providing a ...
Posted by Michael Wonder on 17 Oct 2025
Immunotherapy for patients with advanced cancers
17 October 2025 - More Australians living with advanced cancer could have access to immunotherapy treatment options, thanks to a ...
Posted by Michael Wonder on 17 Oct 2025
First HIV prevention injection for people unable to have daily PrEP recommended
17 October 2025 - A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small ...
Posted by Michael Wonder on 17 Oct 2025
Same time decisions on licensing and value - what pharmaceutical companies need to know
10 October 2025 - Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and ...
Posted by Michael Wonder on 16 Oct 2025
Recommendations made by the PBAC - September 2025
17 October 2025 - Recommendations made by the PBAC in September 2025 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 16 Oct 2025
PHARMAC cuts red tape to improve access to medicines for thousands of New Zealanders
16 October 2025 - PHARMAC is removing unnecessary renewal requirements for selected Special Authority medicines and products, making it easier ...
Posted by Michael Wonder on 11 Oct 2025
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
10 October 2025 - Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them ...
Posted by Michael Wonder on 10 Oct 2025
DUSC utilisation analysis public release documents (April 2025)
10 October 2025 - The utilisation analysis public release documents from the April 2025 DUSC meeting are now available. ...